Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
  2. Authors contributed equally to this work.
  3. Department of Sleep Medicine, Shandong Mental Health Center, Jinan, China
  4. Authors contributed equally to this work.
  5. Department of Psychiatry, Hebei Province Rong-Jun hospital, Baoding, China
  6. Department of Psychiatry, Hebei Province Rong-Jun hospital, Baoding, China
  7. Department of Psychiatry, Hebei Province Rong-Jun hospital, Baoding, China
  8. Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
  9. Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, China
  10. Corresponding authors: Xiang Yang Zhang, MD, PhD, 16 Lincui Rd, Chaoyang District, Beijing, 100101, China ([email protected]) and Mei Hong Xiu, PhD, Changping District, Beijing, 100096, China ([email protected]).
  11. CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
  12. Corresponding authors: Xiang Yang Zhang, MD, PhD, 16 Lincui Rd, Chaoyang District, Beijing, 100101, China ([email protected]) and Mei Hong Xiu, PhD, Changping District, Beijing, 100096, China ([email protected]).
  1. Cheng Z, Yuan Y, Han X, et al. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes. J Psychopharmacol. 2019;33(10):1227–1236. PubMed CrossRef
  2. Cui D, Peng Y, Zhang C, et al. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. J Clin Invest. 2018;128(11):4997–5007. PubMed CrossRef
  3. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. PubMed CrossRef
  4. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–1403. PubMed CrossRef
  5. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. PubMed CrossRef
  6. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60–70. PubMed CrossRef
  7. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611–621. PubMed CrossRef
  8. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70(12):1179–1187. PubMed CrossRef
  9. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25(12):1035–1059. PubMed CrossRef
  10. Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104(9):3456–3459. PubMed CrossRef
  11. Tian Y, Liu D, Wang D, et al. Obesity in Chinese patients with chronic schizophrenia: prevalence, clinical correlates and relationship with cognitive deficits. Schizophr Res. 2019;215:270–276. PubMed
  12. MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622. PubMed CrossRef
  13. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149(1):68–72. PubMed CrossRef
  14. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22(3):244–251. PubMed CrossRef
  15. Ascher-Svanum H, Stensland MD, Kinon BJ, et al. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol. 2005;19(suppl 6):110–117. PubMed CrossRef
  16. Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry. 2006;163(7):1276–1279. PubMed CrossRef
  17. Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011;128(1-3):166–170. PubMed CrossRef
  18. Kemp DE, Correll CU, Tohen M, et al. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol. 2013;23(8):522–530. PubMed CrossRef
  19. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992;149(5):689–690. PubMed CrossRef
  20. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 2003;59(1):19–27. PubMed CrossRef
  21. Procyshyn RM, Wasan KM, Thornton AE, et al; Clozapine and Risperidone Enhancement Study Group. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci. 2007;32(5):331–338. PubMed
  22. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry. 1994;55(suppl B):157–160. PubMed
  23. Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153(6):817–819. PubMed CrossRef
  24. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5(4):437–440. PubMed CrossRef
  25. Phillips MR, Zhang J, Shi Q, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373(9680):2041–2053. PubMed CrossRef
  26. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995–1003. PubMed CrossRef
  27. Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168–1178. PubMed CrossRef
  28. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
  29. Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2005;5(1):3. PubMed CrossRef
  30. Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol. 1959;20(1):53–57. PubMed
  31. Holden JM, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics. 1970;11(6):551–561. PubMed CrossRef
  32. Garyfallos G, Dimelis D, Kouniakis P, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry. 2003;18(6):320–321. PubMed CrossRef
  33. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187(6):537–543. PubMed CrossRef
  34. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010;119(1-3):131–137. PubMed CrossRef
  35. Chukhin E, Terevnikov V, Takala P, et al. Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism? Nord J Psychiatry. 2016;70(3):190–194. PubMed CrossRef
  36. Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. PubMed
  37. Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20–41. PubMed CrossRef
  38. Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418–1437. PubMed CrossRef
  39. Tiwari AK, Zhang D, Pouget JG, et al. Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. World J Biol Psychiatry. 2018;19(suppl 3):S97–S105. PubMed CrossRef
  40. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159(6):1058–1060. PubMed CrossRef
  41. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184(1):58–62. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now